Alanine	B:C0001899
Aminotransferase	I:C0001899

Is	O
a	O
Marker	B:C0005516
of	O
Lipotoxicity	O
Consequences	O
and	O
Hyperandrogenemia	O
in	O
Women	O
with	O
Polycystic	O
Ovary	I:C0032460
Syndrome	I:C0032460
.	O

Is	O
a	O
Marker	O
of	O
Lipotoxicity	B:C0039082
Consequences	O
and	O
Hyperandrogenemia	O
in	O
Women	O
with	O
Polycystic	O
Ovary	I:C0032460
Syndrome	I:C0032460
.	O

Is	O
a	O
Marker	O
of	O
Lipotoxicity	O
Consequences	O
and	O
Hyperandrogenemia	B:C1299574
in	O
Women	O
with	O
Polycystic	O
Ovary	I:C0032460
Syndrome	I:C0032460
.	O

Is	O
a	O
Marker	O
of	O
Lipotoxicity	O
Consequences	O
and	O
Hyperandrogenemia	O
in	O
Women	B:C0043210
with	O
Polycystic	O
Ovary	I:C0032460
Syndrome	I:C0032460
.	O

Is	O
a	O
Marker	O
of	O
Lipotoxicity	O
Consequences	O
and	O
Hyperandrogenemia	O
in	O
Women	O
with	O
Polycystic	B:C0032460
Ovary	I:C0032460
Syndrome	I:C0032460
.	O

Several	O
studies	B:C2603343
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	I:C0001899
(	O
Alanine	O
aminotransferase	I:C0001899
)	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
(	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
)	O
compared	O
with	O
control	O
subjects	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	B:C0001899
aminotransferase	I:C0001899
(	O
Alanine	O
aminotransferase	I:C0001899
)	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
(	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
)	O
compared	O
with	O
control	O
subjects	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	I:C0001899
(	O
Alanine	B:C0001899
aminotransferase	I:C0001899
)	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
(	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
)	O
compared	O
with	O
control	O
subjects	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	I:C0001899
(	O
Alanine	O
aminotransferase	I:C0001899
)	O
in	O
women	B:C0043210
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
(	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
)	O
compared	O
with	O
control	O
subjects	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	I:C0001899
(	O
Alanine	O
aminotransferase	I:C0001899
)	O
in	O
women	O
with	O
polycystic	B:C0032460
ovary	I:C0032460
syndrome	I:C0032460
(	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
)	O
compared	O
with	O
control	O
subjects	O
.	O

Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	I:C0001899
(	O
Alanine	O
aminotransferase	I:C0001899
)	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
(	O
polycystic	B:C0032460
ovary	I:C0032460
syndrome	I:C0032460
)	O
compared	O
with	O
control	O
subjects	O
.	O

Plasma	B:C1272112
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	O
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	B:C0005516
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	O
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	B:C0205054
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	O
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	B:C0039082
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	O
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	B:C0205054
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	O
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	B:C0015695
steatosis	I:C0015695
and	O
hepatic	O
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	B:C0205054
insulin	O
resistance	I:C0021655
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	O
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	O
steatosis	I:C0015695
and	O
hepatic	O
insulin	B:C0021655
resistance	I:C0021655
.	O

Retrospective	B:C0282574
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
women	O
,	O
the	O
relationship	O
between	O
ALT	O
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Retrospective	O
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	B:C0032460
ovary	I:C0032460
syndrome	I:C0032460
women	O
,	O
the	O
relationship	O
between	O
ALT	O
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Retrospective	O
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
women	B:C0043210
,	O
the	O
relationship	O
between	O
ALT	O
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Retrospective	O
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
women	O
,	O
the	O
relationship	O
between	O
ALT	B:C1272112
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Retrospective	O
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
women	O
,	O
the	O
relationship	O
between	O
ALT	O
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	B:C0039082
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Retrospective	O
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
women	O
,	O
the	O
relationship	O
between	O
ALT	O
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B:C0428568
and	O
using	O
the	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Retrospective	O
chart	I:C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
women	O
,	O
the	O
relationship	O
between	O
ALT	O
levels	I:C1272112
and	O
measures	O
of	O
lipotoxicity	O
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	O
and	O
using	O
the	O
oral	B:C0029161
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
.	O

Women	B:C0043210
(	O
n	O
=	O
132	O
)	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	I:C1305855
index	I:C1305855
of	O
34.1	O
kg	O
/	O
m(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	O
syndrome	I:C0039082
(	O
metabolic	O
syndrome	I:C0039082
)	O
.	O

Women	O
(	O
n	O
=	O
132	O
)	O
with	O
polycystic	B:C0032460
ovary	I:C0032460
syndrome	I:C0032460
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	I:C1305855
index	I:C1305855
of	O
34.1	O
kg	O
/	O
m(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	O
syndrome	I:C0039082
(	O
metabolic	O
syndrome	I:C0039082
)	O
.	O

Women	O
(	O
n	O
=	O
132	O
)	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
of	O
34.1	O
kg	O
/	O
m(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	O
syndrome	I:C0039082
(	O
metabolic	O
syndrome	I:C0039082
)	O
.	O

Women	O
(	O
n	O
=	O
132	O
)	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	I:C1305855
index	I:C1305855
of	O
34.1	O
kg	O
/	O
m(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	B:C0039082
syndrome	I:C0039082
(	O
metabolic	O
syndrome	I:C0039082
)	O
.	O

Women	O
(	O
n	O
=	O
132	O
)	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	I:C1305855
index	I:C1305855
of	O
34.1	O
kg	O
/	O
m(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	O
syndrome	I:C0039082
(	O
metabolic	B:C0039082
syndrome	I:C0039082
)	O
.	O

ALT	B:C1272112
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	B:C3639411
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	B:C0023822
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	B:C0918012
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	B:C0430022
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	B:C0443483
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	B:C1261430
glucose	I:C1261430
and	O
triglyceride	O
levels	I:C0428475
.	O

ALT	O
levels	I:C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	O
model	I:C3639411
assessment	I:C3639411
for	I:C3639411
insulin	I:C3639411
resistance	I:C3639411
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	I:C0023822
C	I:C0023822
(	O
r	O
=	O
-	O
0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	I:C0918012
(	O
-	O
0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	O
secretion	I:C0430022
-	I:C0430022
sensitivity	I:C0430022
index	I:C0430022
-	I:C0430022
2	I:C0430022
(	O
-	O
0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	I:C0443483
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	I:C1261430
and	O
triglyceride	B:C0428475
levels	I:C0428475
.	O

Alanine	B:C0001899
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
metabolic	O
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	O
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Alanine	O
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	B:C1261430
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
metabolic	O
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	O
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Alanine	O
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	B:C0428475
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
metabolic	O
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	O
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Alanine	O
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	B:C0043210
with	O
the	O
metabolic	O
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	O
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Alanine	O
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
metabolic	B:C0039082
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	O
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Alanine	O
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
metabolic	O
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	B:C0021655
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	O
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Alanine	O
aminotransferase	I:C0001899
cutoff	O
≥	O
24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	I:C1261430
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	I:C0428475
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
metabolic	O
syndrome	I:C0039082
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	I:C0021655
body	I:C0021655
insulin	I:C0021655
resistance	I:C0021655
(	O
Matsuda	B:C0918012
index	I:C0918012
<	O
12.3	O
L(	O
2)	O
·10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O

Plasma	B:C1272112
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	B:C0023884
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	B:C0039082
but	O
also	O
of	O
systemic	O
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	B:C0039082
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	B:C1299574
in	O
women	O
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	O
in	O
women	B:C0043210
with	O
polycystic	O
ovary	I:C0032460
syndrome	I:C0032460
.	O

Plasma	O
ALT	I:C1272112
levels	I:C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	O
lipotoxicity	O
but	O
also	O
of	O
systemic	O
lipotoxic	I:C0039082
consequences	O
and	O
hyperandrogenemia	O
in	O
women	O
with	O
polycystic	B:C0032460
ovary	I:C0032460
syndrome	I:C0032460
.	O

Although	O
it	O
requires	O
validation	B:C1519941
in	O
another	O
study	O
,	O
an	O
Alanine	O
aminotransferase	I:C0001899
cutoff	O
of	O
≥	O
24	O
IU/L	O
may	O
help	O
clinicians	O
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O

Although	O
it	O
requires	O
validation	O
in	O
another	O
study	B:C2603343
,	O
an	O
Alanine	O
aminotransferase	I:C0001899
cutoff	O
of	O
≥	O
24	O
IU/L	O
may	O
help	O
clinicians	O
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O

Although	O
it	O
requires	O
validation	O
in	O
another	O
study	O
,	O
an	O
Alanine	B:C0001899
aminotransferase	I:C0001899
cutoff	O
of	O
≥	O
24	O
IU/L	O
may	O
help	O
clinicians	O
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O

Although	O
it	O
requires	O
validation	O
in	O
another	O
study	O
,	O
an	O
Alanine	O
aminotransferase	I:C0001899
cutoff	O
of	O
≥	O
24	O
IU/L	O
may	O
help	O
clinicians	B:C0871685
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O

Although	O
it	O
requires	O
validation	O
in	O
another	O
study	O
,	O
an	O
Alanine	O
aminotransferase	I:C0001899
cutoff	O
of	O
≥	O
24	O
IU/L	O
may	O
help	O
clinicians	O
identify	O
women	B:C0043210
with	O
increased	O
metabolic	O
risks	O
.	O

